FDA 483 - Medtronic Neuromodulation - June 30, 2017
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Medtronic Neuromodulation in Minneapolis, MN, identified significant deficiencies in the firm's quality system. The company failed to adequately investigate complaints related to software revisions for the Synchromed II Pump, which led to patient overdose symptoms. Additionally, the firm's corrective and preventive action (CAPA) procedures were found to be inadequately established, with issues in verifying effectiveness and adhering to root cause identification timeframes.
ID · 54b630ae-a2e2-454e-ba6e-55435aca525c